Skip to content
AiSeekAiSeek
Sign in

Company

Vaxcyte

FollowOpen structure mapAsk about thisResearch this company

Structure of Vaxcyte

Vaxcyte

Company

4 connections
UpstreamSupply and dependency
OwnProducts and technology
PeersCompetition and partners
Relationship began2026
VaxcyteCompany · 4 connections
Layer 1

UpstreamSupply and dependency1

PeersCompetition and partners2

OwnProducts and technology1

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

Showing 1 to 6 of 6

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 2
usesXpressCF®

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform

GlobeNewswire public company news · 2026-10-07 10:48

View evidence
  • CompanyGlobeNewswire public company news2026-10-07 10:48
    Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform
    View source
  • CompanyGlobeNewswire public company news2026-10-07 10:48
    Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines
    View source
FactEvidence 1
expected gross proceeds from common stock and pre funded warrants offeringapproximately $500 million USD

The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million

GlobeNewswire public company news · 2026-10-07 10:48

View evidence
  • CompanyGlobeNewswire public company news2026-10-07 10:48
    The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million
    View source
FactEvidence 1
expected gross proceeds from notes offering$500 million USD

the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million

GlobeNewswire public company news · 2026-10-07 10:48

View evidence
  • CompanyGlobeNewswire public company news2026-10-07 10:48
    the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million
    View source
FactEvidence 2
producesVAX-31

No public evidence summary is available.

BioPharma Dive · STAT · 2026-10-05 21:52

View evidence
FactEvidence 1
market value12 billion

No public evidence summary is available.

BioPharma Dive · 2026-10-05 21:52

View evidence
FactEvidence 2
competes withPfizer

No public evidence summary is available.

BioPharma Dive · STAT · 2026-10-05 21:52

View evidence

Showing 1 to 6 of 9

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Not available: Company signals · Financials · Filings · Guidance